---
layout: post
title: "Special Considerations, Incentives, and Programs To Support the Approval of New Animal Drugs for Minor Uses and for Minor Species; Guidance for Industry; Availability"
date: 2026-02-05 18:58:04 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-28287
original_published: 2023-12-22 00:00:00 +0000
significance: 8.00
---

# Special Considerations, Incentives, and Programs To Support the Approval of New Animal Drugs for Minor Uses and for Minor Species; Guidance for Industry; Availability

**Published:** February 05, 2026 18:58 UTC
**Source:** Federal Register
**Original Published:** December 22, 2023 00:00 UTC
**Document Number:** 2023-28287

## Summary

The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a final guidance for industry (GFI) #61 entitled "Special Considerations, Incentives, and Programs to Support the Approval of New Animal Drugs for Minor Uses and for Minor Species." This guidance is intended to assist those interested in pursuing FDA approval of new animal drugs intended for minor uses in major species or for use in minor species (MUMS drugs). It outlines the basic statutory and regulatory requirements and special considerations for these approvals and describes the incentives available to encourage the development of MUMS drugs.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/12/22/2023-28287/special-considerations-incentives-and-programs-to-support-the-approval-of-new-animal-drugs-for-minor)
- API: https://www.federalregister.gov/api/v1/documents/2023-28287

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
